

# OFFER DOCUMENT ENTITLEMENT ISSUE

---

Medibio Limited  
ACN 008 130 336

For a non-renounceable pro-rata entitlement issue of one (1) Offer Share for every three (3) Shares held by Eligible Shareholders registered at the Record Date at an Issue Price of \$0.005 (0.5 cents) per Offer Share (**Offer**) with one free Attaching Option for every two (2) Offer Shares issued to raise up to approximately \$3.4 million (before costs).

The Offer opens at 9.00am (AEDT) on Monday, 31 January 2022

The Offer closes at 5.00pm (AEDT) on Friday, 18 February 2022

The Offer is partially underwritten by CPS Capital Group Pty Ltd ACN 088 055 636.

## **NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES**

This Offer Document dated 20 January 2022 and the accompanying personalised Entitlement and Acceptance Form contains important information. Please read both the Offer Document and the personalised Entitlement and Acceptance Form carefully and in their entirety and call your professional adviser or Medibio Limited (**Company**) if you have any queries. In particular, Eligible Shareholders should refer to the risk factors set out in Section 6 of this document. If you do not understand these documents, or are in doubt as to how to act, you should consult your financial or other professional adviser before making any investment decision.

This Offer Document is not a prospectus prepared in accordance with the Corporations Act and has not been lodged with ASIC. Accordingly, this Offer Document does not necessarily contain all of the information which a prospective investor may require to make an investment decision and it does not contain all of the information which would otherwise be required to be disclosed in a prospectus or other disclosure document. As the Company is a listed disclosing entity which meets the requirements of section 708AA of the Corporations Act, the Offer will be made without a prospectus. Neither ASIC nor ASX, nor any of their officers or employees takes responsibility for this Offer or the merits of the investment to which this Offer relates.

## Contents

1. Key details of Offer	1
2. Managing Director's Letter	3
3. Important Information	5
4. Details of the Offer	8
5. Purpose and effect of the Offer	15
6. Risk Factors	19
7. Additional information	24
8. Definitions	32
9. Corporate Directory	35

## 1. Key details of Offer

### 1.1 Key terms of Offer

Detail	Terms
Issue Price	\$0.005 (0.5 cents)
Entitlement	1 Offer Share for every 3 Shares held at the Record Date
Attaching Option	For each 2 Offer Shares issued under the Entitlement Offer, the Company will also grant 1 free Attaching Option for no additional consideration
Shortfall Offer	Eligible Shareholders, who apply for their full Entitlement, may apply for 'Additional Shares', provided that the issue of those Additional Shares will not result in a breach of the Listing Rules or any applicable law.
Maximum number of Offer Shares to be issued	687,018,109 Offer Shares
Maximum gross proceeds of Offer	\$3,435,091
Maximum number of Shares on issue following the Offer and Placement	2,938,118,482 Shares

The above figures assume that no existing Options will be exercised prior to the Record Date. As at the date of this Offer Document there are 306,208,622 Options on issue.

### 1.2 Key indicative dates

Action	Date
Announcement of Offer	Wednesday, 15 December 2021
Lodgement of Appendix 3B with ASX	Wednesday, 15 December 2021
Dispatch Notice of EGM	Thursday, 6 January 2022
Cleansing Notice and Lodgement of Offer Document with ASX	Thursday, 20 January 2022
Letter to Ineligible Shareholders regarding Offer despatched	Friday, 21 January 2022
Trading on ex basis	Monday, 24 January 2022
Record Date for Offer and determining Entitlements	Tuesday, 25 January 2022

Offer Opening Date	9.00am (AEDT), Monday, 31 January 2022
Offer Document despatched to Eligible Shareholders and Company announces despatch has been completed	Monday, 31 January 2022
Closing Date	5.00pm (AEDT), Friday, 18 February 2022
Offer Shares quoted on a deferred settlement basis	Monday, 21 February 2022
Announcement of results of Offer	Friday, 25 February 2022
Issue date of Offer Shares	12.00pm (AEDT), Friday, 25 February 2022
Quotation of Offer Shares	Monday, 28 February 2022

The above dates are indicative only and may be subject to change. Subject to the Corporations Act, the Listing Rules and other applicable laws, the Directors reserve the right:

- (a) to vary the dates of the Offer in consultation with the Underwriter; or
- (b) not to proceed with the whole or part of the Offer at any time prior to issue of the Offer Shares.

In the event the Directors decide not to proceed with the whole or part of the Offer, Application Monies (without interest) will be returned in full to the Applicants.

An extension of the Closing Date for the Offer will delay the anticipated date for issue of the Offer Shares. The commencement of quotation of Offer Shares is subject to confirmation from ASX.

Eligible Shareholders wishing to participate in the Offer are encouraged to submit their Entitlement and Acceptance Form and make payment of the appropriate Application Monies as soon as possible after the Offer opens.

You cannot, in most circumstances, withdraw an Application once it has been accepted. No cooling-off rights apply to the Offer.

## 2. Managing Director's Letter

---

Dear Shareholders,

### Offer

On behalf of the Board, I am pleased to invite you to participate in this partially underwritten non-renounceable pro-rata entitlement offer of one (1) Offer Share for every three (3) Shares (**Entitlement**) held at the Record Date at an issue price of \$0.005 (0.5 cents) with one free Attaching Option for every two (2) Offer Shares to raise up to approximately \$3.4 million (before costs). Your Entitlement will provide you with the opportunity to increase your exposure to the upside of the Company moving forward.

Where fractions arise in the calculation of an Entitlement, they have been rounded up to the next whole number of Offer Shares.

The Offer Shares will be issued under exception 1 and 2 of ASX Listing Rule 7.2 and exception 1 of ASX Listing Rule 10.12 which means that shareholder approval under ASX Listing Rule 7.1 and 10.11 (respectively) will not be required for the issue.

The Offer will be open to those Eligible Shareholders who are on the Company's share register at 7:00pm (Melbourne time) on Tuesday, 25 January 2022 and that have a registered address in Australia or New Zealand; and are not located in the US and are not a US Person or acting for the account of or benefit of a person in US or a US Person. Eligible Shareholders who subscribe for their full Entitlement may also apply for Offer Shares in excess of their Entitlement (**Additional Shares**) in accordance with the Shortfall Offer.

The Offer is partially underwritten by CPS Capital Group Pty Ltd ACN 088 055 636.

The proceeds of the Offer, in conjunction with funds raised from the Placement undertaken by the Company on 15 December 2021 (for the issue of 450,049,250 Shares, with (1) one free Attaching Option for every two (2) Placement Shares issued to sophisticated investors and professional investors at an issue price of \$0.005 (0.5 cents) to raise \$2,250,247 (before costs and expenses) (**Placement**) will be used to:

- (a) finalise the depressive burden validation trial and submit the data for FDA approval pursuant to a De Novo application;
- (b) establish the depressive burden trial with Medibio's existing research partner, Medbridge Health, for monitoring of sleep disturbance patients in the home environment;
- (c) establish the trial with a commercial partner to monitor the effects of pharmaceuticals in psychiatric patients;
- (d) increase the promotion, sales and marketing activities for the Company's corporate and consumer products, ilumen and LUCA, particularly in the USA; and
- (e) general working capital.

I encourage all Shareholders to review closely our Company Update presentation announced on 15 December 2021 for more details on the Company's plans and activities.

### Non-tradable rights

Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferrable. Eligible Shareholders who do not take up their Entitlement will not receive any value in respect of those Entitlements.

### Low-docs offer

The Offer is to be made under s708AA of the Corporations Act and the Offer Document has been lodged with the ASX. A copy of that document can be accessed on the ASX website or the

Company's website and is anticipated to be despatched to Eligible Shareholders (with personalised Entitlement and Acceptance Forms) on or before Monday, 31 January 2022.

Both the Offer Shares and Attaching Options are continuously quoted securities, and the Company is therefore able to rely on s708AA of the Corporations Act provided that it satisfies the requirements of that section.

### **How to apply**

The Offer is scheduled to close at 5:00pm (AEDT) on Friday, 18 February 2022. To participate in the Offer, you must have applied for Offer Shares online at the Offer Website at <https://mcb2022entoffer.thereachagency.com> so that your completed Entitlement and Acceptance Form and BPAY® payment (or if applicable, EFT payment) of Application Monies is received by this time. Shareholders recorded on the share register with an address outside Australia or New Zealand are not eligible to participate in the Offer.

Payment by cheque or cash will not be accepted.

### **Conclusion**

Potential investors should be aware that subscribing for the Offer Shares involves a number of risks. The key risk factors of which investors should be aware are set out in section 6 of this Offer Document. Investors should carefully consider the risk factors that affect the Company specifically and the industry in which it operates.

On behalf of the Board, I would like to thank you for your continued support and invite you to seriously consider this compelling investment opportunity.

Yours Sincerely,

A handwritten signature in black ink, appearing to read 'Claude Solitario', written in a cursive style.

Claude Solitario  
Managing Director & CEO  
Medibio Limited

### **3. Important Information**

---

This Offer Document is dated 20 January 2022. This Offer Document is not a prospectus, product disclosure statement or other form of disclosure document under the Corporations Act (or any other law) and has not been lodged with ASIC. The Offer Document is for information purposes only.

This Offer Document does not purport to contain all the information that you may require to evaluate a possible application for Offer Shares, nor does it contain all the information which would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act (or any other law). It should be read in conjunction with the Company's other periodic statements and continuous disclosure announcements lodged with ASX.

It is also not financial product advice and has been prepared without taking into account your investment objectives, financial circumstances or particular needs. The Company is not licensed to provide financial product advice in respect of the Offer Shares. Neither ASIC nor ASX take responsibility for the contents of this Offer Document.

By returning an Entitlement and Acceptance Form (if applicable) or paying for your Offer Shares and any Additional Shares through BPAY® in accordance with the instructions on the Entitlement and Acceptance Form, you acknowledge that you have read this Offer Document and you have acted in accordance with and agree to the terms of the Offer detailed in this Offer Document.

You should also consider the key risks which is included in this Offer Document at section 6.

#### *References to 'you' and 'your Entitlement'*

In this Offer Document, references to 'you' are references to Eligible Shareholders and references to 'your Entitlement' (or 'your Entitlement and Acceptance Form') are references to the Entitlement and Acceptance Form of Eligible Shareholders.

#### *No Entitlement trading*

Entitlements are non-renounceable and will not be tradable on the ASX or otherwise transferable. Accordingly, you cannot, in most circumstances, withdraw your Application for Offer Shares once it has been accepted.

#### **3.1 Investment decisions**

The information in this Offer Document does not take into account the investment objectives, financial situation or needs of you or any particular investor. The potential tax effects of the Offer will vary between individual investors. Before deciding whether to apply for Offer Shares, you should consider whether they are a suitable investment for you in light of your own investment objectives and financial circumstances and having regard to the merits or risks involved. You should conduct your own independent review, investigation and analysis of Offer Shares the subject of the Offer. If, after reading this Offer Document, you have any questions about the Offer, you should contact your stockbroker, accountant or other independent and appropriately licensed professional adviser.

#### **3.2 Disclaimer**

No person is authorised to give any information or to make any representations in connection with the Offer which is not contained in this Offer Document. Any information or representation not contained in this Offer Document may not be relied on as having been authorised by the Company in connection with the Offer.

### **3.3 Offer is only made in Australia and New Zealand**

This Offer does not constitute an offer in any place in which, or to any person to whom, it would not be lawful to make such an offer. In particular, the Offer (and any Shortfall Offer) is only being made in Australia and New Zealand.

The distribution of this Offer Document in jurisdictions outside Australia may be restricted by law and persons who come into possession of this Offer Document should seek advice on and observe any of these restrictions. Failure to comply with these restrictions may violate securities laws. Applicants who are resident in countries other than Australia should consult their professional advisers as to whether any governmental or other consents are required or whether any other formalities need to be considered and followed. In particular, this Offer Document may not be distributed in the US or any other country except Australia or New Zealand.

The Offer to New Zealand investors is made pursuant to the New Zealand *Securities Act (Overseas Companies) Exemption Notice 2013*. Pursuant to this Act, the only members of the public to whom the Offer Shares are offered in New Zealand are those who, at the time of the Offer, are holders of Shares in the Company.

As the ASX does not operate in New Zealand, the way in which the market operates, the regulation of participants in that market, and the information available to you about the securities and trading may differ from securities markets that operate in New Zealand.

### **3.4 Forward-looking statements**

This Offer Document contains forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties.

These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this Offer Document, are expected to take place.

Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the Directors and management of the Company.

To the maximum extent permitted by law, none of the Company or any person named in this Offer Document or any person involved in the preparation of this Offer Document makes any representation or warranty (express or implied) as to the accuracy or likelihood of fulfilment of any forward looking statement, or any intentions or outcomes expressed or implied in any forward looking statement and disclaim all responsibility and liability for such forward looking statements (including, without limitation, liability for negligence). The Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this Offer Document, except where required by law. You are cautioned not to place undue reliance on any forward looking statement having regard to the fact that the outcome may not be achieved.

Any pro forma financial information (including past performance information) provided in this Offer Document is for information purposes only and is not a forecast of operating results to be expected in any future period. Except as required by law, and only then to the extent so required, neither the Company nor any other person warrants or guarantees the future performance of the Company or any return on any investment made pursuant to this Offer Document.

### **3.5 Risk factors**

Potential investors should be aware that subscribing for Shares in the Company involves a number of risks. The key risk factors of which investors should be aware are set out in section 6 of this Offer Document. Investors should carefully consider the risk factors that



affect the Company specifically and the resources, mining and exploration industry in which it operates.

### **3.6 Defined terms and time**

Terms and abbreviations used in this Offer Document are defined in section 8 of this Offer Document. All financial amounts shown in this Offer Document are expressed in Australian dollars unless otherwise stated.

Notwithstanding any references to the contrary, all references to time in this Offer Document are to Melbourne time.

### **3.7 Publicly available information**

The Offer Document should be read in conjunction with the Company's continuous disclosure announcements made to the ASX available from the ASX website (at [www.asx.com.au](http://www.asx.com.au) - ASX Code: MEB). The Company may release further announcements after the date of this Offer Document which may be relevant to your consideration of the Offer.

### **3.8 Past performance**

Investors should note that past performance, including past Share price performance, cannot be relied on as an indicator of, and provides no guidance as to, future Company performance, including future Share performance.

### **3.9 Withdrawal**

The Company reserves the right to withdraw the Offer at any time before the issue of Offer Shares under the Offer, in which case Medibio will refund any Application Monies received.

## 4. Details of the Offer

---

### 4.1 Purpose of the Offer

The purpose of this Offer is to:

- (a) raise additional working capital for the Company to undertake the items listed in the Managing Director's letter in section 2 of this Offer Document; and
- (b) recognise Shareholders' ongoing support of the Company and provide the opportunity for Eligible Shareholders to participate in a discounted rights issue.

### 4.2 Entitlement and amount to be raised

The Company is undertaking a partially underwritten non-renounceable pro-rata entitlement issue of one (1) Offer Share for every three (3) Shares (**Entitlement**) held by Eligible Shareholders registered as at the Record Date at an issue price of \$0.005 (0.5 cents) per Offer Share (**Offer**).

Where fractions arise in the calculation of an Entitlement, they have been rounded up to the next whole number of Offer Shares.

Based on the capital structure of the Company as at the date of this Offer Document, a maximum of 687,018,109 Offer Shares will be issued pursuant to this Offer to raise up to approximately \$3.4 million (before costs).

All Offer Shares issued will have the rights attaching to those securities as set out in section 4.8.

The intended use of funds raised under the Offer is set out in section 5.1 of this Offer Document.

The Directors may, at any time, decide to withdraw this Offer Document and the Offer of Offer Shares made under it, in which case the Company will return all Application Monies (without interest) in accordance with the Corporations Act.

### 4.3 Issue price

The issue price is \$0.005 (0.5 cents) for each Offer Share payable in full in Australian currency via BPAY® payment (or if applicable, via EFT payment).

Your completed Entitlement and Acceptance Form must be submitted online at the Offer Website located at <https://meb2022entoffer.thereachagency.com> and your payment must be received by the Company via BPAY® payment (or if applicable, via EFT payment) by no later than 5.00 pm AEDT on the Closing Date.

**Payment by cheque or cash will not be accepted.**

### 4.4 Minimum subscription

There is no minimum subscription in respect of the Offer.

### 4.5 Underwriting

The Offer is partially underwritten by the Underwriter for an amount up to \$1 million. Subject to the terms of the Underwriting Agreement, the Underwriter will lodge or cause to be lodged with the Company, Applications for any Offer Shares not subscribed for by Eligible Shareholders. The Underwriter is entitled to, in consultation with the Company, nominate who is to receive Offer Shares not subscribed for as Entitlements by Eligible Shareholders.

A summary of the other material terms of the Underwriting Agreement is set out in Section 7.12 of this Offer Document.

#### **4.6 Eligibility to participate in Offer**

The Offer is being offered to Eligible Shareholders only. Eligible Shareholders are persons who are registered as a holder of Shares as at the Record Date that:

- (a) have a registered address in Australia or New Zealand; and;
- (b) are not located in US and are not a US Person or acting for the account of or benefit of a person in US or a US Person,

**(Eligible Shareholders).**

Shareholders who are not Eligible Shareholders are Ineligible Shareholders.

The Company has decided that it is unreasonable to make offers under the Offer to Shareholders who have a registered address outside Australia or New Zealand having regard to the number of such holders in those places and the number and the value of the Offer Shares that they would be offered, and the costs of complying with the relevant legal and regulatory requirements in those places. The Company may (in its absolute discretion) extend the Offer to Shareholders who have registered addresses outside of Australia or New Zealand in accordance with applicable law.

Shareholders with a registered address in New Zealand must note the selling restrictions set out in Section 4.17 of this Offer Document.

Eligible Shareholders will receive a personalised Entitlement and Acceptance Form setting out their Entitlement which will accompany the copy of this Offer Document sent to them. Where fractions arise in the calculation of an Entitlement, they have been rounded up to the next whole number of Offer Shares.

Shareholders who are not Eligible Shareholders, will not be entitled to participate in the Entitlement Offer or to subscribe for Offer Shares.

#### **4.7 Optionholders**

Optionholders will not be able to participate in the Offer unless they:

- (a) have become entitled to exercise their existing Options under the terms of their issue and do so, so they are registered as holders of Shares prior to the Record Date; and
- (b) participate in the Offer as a result of being a holder of Shares registered on the register of the Company at the Record Date.

#### **4.8 Rights attaching to Shares**

Shares issued pursuant to the Offer will be fully paid ordinary and rank equally with all other issued Shares, including in respect of dividends.

The rights attaching to Shares are set out in the Constitution and are regulated by the Corporations Act, the ASX Listing Rules and general law.

#### **4.9 Non-renounceable offer**

The rights to Offer Shares are non-renounceable. Accordingly, there will be no trading rights on the ASX (or any other exchange) and you may not dispose of your rights to subscribe for Offer Shares to any other party. If you do not take up your Entitlement to Offer Shares by the Closing Date, the Offer to you will lapse, you will receive no benefit and your interest in the Company may be diluted.

#### 4.10 Acceptance

Your acceptance of the Offer must be made on the Entitlement and Acceptance Form which can be accessed at <https://meb2022entoffer.thereachagency.com>.

The number of Offer Shares to which Eligible Shareholders are entitled (your Entitlement) is shown on your personalised Entitlement and Acceptance Form, which along with this Offer Document is accessible at <https://meb2022entoffer.thereachagency.com>.

If you do not take up your Entitlement in full, then your percentage holding in the Company will be diluted.

You may participate in the Offer as follows:

- (a) if you wish to take up your Entitlement in **full** and, if you do so, also **apply for Additional Shares** (refer to section 4.13 of this Offer Document);
  - (i) apply for your full Entitlement for Offer Shares and the Additional Shares you wish to apply for (being more than your Entitlement as specified on the Entitlement and Acceptance Form) online by visiting the Offer Website at <https://meb2022entoffer.thereachagency.com>. You will need to provide your Securityholder Reference Number (**SRN**) or Holder Identification Number (**HIN**) and postcode to access the online application system and follow the instructions provided including making payment by BPAY® (or EFT, if applicable). You will be deemed to have applied for that number of Additional Shares which in aggregate with your Entitlement is covered in full by your Application Monies. In order to participate in the Shortfall Offer and subscribe for Additional Shares, you must also apply for your Entitlement in full; and
  - (ii) arrange payment by:
    - (A) **BPAY®** as instructed for the appropriate Application Monies for your Entitlement of Offer Shares plus the number of Additional Shares you have applied for (at \$0.005 (0.5 cents) per Offer Share and Additional Shares); or
    - (B) for New Zealand Shareholders only, that are unable to pay via **BPAY®**, please contact the Share Registry on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) for alternative electronic funds transfer (**EFT**) payment arrangements for the appropriate Application Monies for your Entitlement of Offer Shares plus the number of Additional Shares you have applied for (at \$0.005 (0.5 cents) per Offer Share and Additional Shares); or
- (b) if you wish to take up your Entitlement in **full** without applying for Additional Shares;
  - (i) apply for your full Entitlement for Offer Shares online by visiting the Offer Website at <https://meb2022entoffer.thereachagency.com>. You will need to provide your SRN or HIN and postcode to access the online application system and follow the instructions provided including making payment by BPAY® (or EFT, if applicable); and
  - (ii) arrange payment by:
    - (A) **BPAY®** as instructed for the appropriate Application Monies for your Entitlement of Offer Shares you have applied for (at \$0.005 (0.5 cents) per Offer Share); or
    - (B) for New Zealand Shareholders only, that are unable to pay via **BPAY®**, please contact the Share Registry on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) for alternative EFT payment arrangements for the appropriate Application Monies for

your Entitlement of Offer Shares (at \$0.005 (0.5 cents) per Offer Share); or

- (c) if you wish to take up **part**, but not all of your Entitlement;
  - (i) apply for the number of Offer Shares you wish to subscribe for online by visiting the Offer Website at <https://meb2022entoffer.thereachagency.com>. You will need to provide your SRN or HIN and postcode to access the online application system and follow the instructions provided including making payment by BPAY® (or EFT, if applicable); and
  - (ii) arrange payment by:
    - (A) **BPAY®** as instructed for the appropriate Application Monies for the number of Offer Shares you have applied for (at \$0.005 (0.5 cents) per Offer Share); or
    - (B) for New Zealand Shareholders only, that are unable to pay via **BPAY®**, please contact the Share Registry on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) for alternative EFT payment arrangements for the appropriate Application Monies for the number of Offer Shares you have applied for (at \$0.005 (0.5 cents) per Offer Share); or
- (d) if you do not wish to accept all or part of your Entitlement, you are not obligated to do anything in response to the Offer.

**Payment by cheque or cash will not be accepted.**

The Offer is non-renounceable. Accordingly, a Shareholder may not sell or transfer all or part of their Entitlement.

**4.11 Implications of an acceptance**

The payment of any Application Monies by BPAY® or EFT (if applicable) will be taken by the Company to constitute a representation by you that:

- (a) you have received a copy of this Offer Document and the accompanying Entitlement and Acceptance Form, and read them both in their entirety;
- (b) such payment constitutes a binding and irrevocable offer to apply for Offer Shares (plus any Additional Shares) on the terms and conditions set out in this Offer Document and/or the Entitlement and Acceptance Form and, once lodged or paid, cannot be withdrawn; and
- (c) you acknowledge that once the Entitlement and Acceptance Form is returned or a BPAY® payment or an EFT payment instruction (if applicable) is given in relation to any Application Monies, the Application may not be varied or withdrawn except as required by law.

**4.12 Payment by BPAY® and EFT**

For payment by BPAY®, please follow the instructions on the Entitlement and Acceptance Form which can be accessed at <https://meb2022entoffer.thereachagency.com>. You can only make a payment via BPAY® if you are the holder of an account with an Australia financial institution that supports BPAY® transactions or for New Zealand Shareholders only, if you do not have an account that supports BPAY® transactions to an Australian bank account then please contact the Share Registry on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) for alternative EFT payment arrangements. Please note that by paying by BPAY® or EFT:

- (a) you do not need to submit the Entitlement and Acceptance Form but are taken to have made the declarations on that Entitlement and Acceptance;

- (b) if you do not pay for your Entitlement in full, you are deemed to have taken up your Entitlement in respect of such whole number of Offer Shares which is covered in full by your Application Monies; and
- (c) if you pay more than is required to subscribe for your Entitlement, you will be taken to have applied for Additional Shares (if any) under the Shortfall Offer, to the extent of the excess.

**It is your responsibility to ensure that your BPAY® or EFT payment is received by the Share Registry by no later than 5.00pm (AEDT) on the Closing Date. You should be aware that your financial institution may implement earlier cut-off times with regards to electronic payment and you should therefore take this into consideration when making payment.** Any Application Monies received for more than your final allocation of Offer Shares (including any Additional Shares) (only where the amount is \$1.00 or greater) will be refunded. No interest will be paid on any Application Monies received or refunded.

**Payment by cheque or cash will not be accepted.**

The Offer is non-renounceable. Accordingly, a Shareholder may not sell or transfer all or part of their Entitlement.

#### **4.13 Shortfall Offer**

Eligible Shareholders who have subscribed for their Entitlement in full may apply for Offer Shares in addition to their Entitlement (**Additional Shares**) in accordance with the Shortfall Offer. Please refer to section 4.10(a) of this Offer Document for further information as to how to apply for Additional Shares above your Entitlement.

Any Additional Shares will be limited to the extent that there are sufficient Offer Shares available after satisfying all Applications received from Eligible Shareholders for Entitlements pursuant to the Offer and allocations made by the Underwriter (i.e. there is a shortfall between the number of Offer Shares applied for under the Offer and the total number of Offer Shares offered to Eligible Shareholders under the Offer). The Company may, in its absolute discretion, determine whether or not to accept any or all applications for Additional Shares by Eligible Shareholders.

It is possible that there will be few or no Additional Shares available, depending on the level of acceptance of Entitlements by Eligible Shareholders and allocations made by the Underwriter in accordance with the terms of the Underwriting Agreement. There is therefore no guarantee that in the event that Additional Shares are available for issue, they will be allocated to all or any of the Eligible Shareholders who have applied for them.

Following the allocation of the Additional Shares, any remaining Offer Shares will be issued to the Underwriter or its nominees in accordance with the Underwriting Agreement.

The Company's decision as to the number of Additional Shares to be allocated to you will be final and binding. The Company may issue to an Applicant a lesser number of Additional Shares or not proceed with the issuing of all or part of the Additional Shares. If the number of Additional Shares is less than the number applied for, surplus Application Monies will be refunded without interest.

#### **4.14 ASX Quotation**

Application for Official Quotation of the Offer Shares and Attaching Options offered pursuant to this Offer Document will be made in accordance with the timetable set out at the commencement of this Offer Document.

The fact that ASX may grant Official Quotation to the Offer Shares or the Attaching Options is not to be taken in any way as an indication of the merits of the Offer or an interest in the Company.

#### **4.15 Allotment**

Shares issued pursuant to the Offer will be allotted in accordance with the ASX Listing Rules and timetable set out in section 1.2 of this Offer Document.

Additional Shares issued will be allotted on a progressive basis. Where the number of Shares issued is less than the number applied for, or where no allotment is made, surplus Application Monies will be refunded (without interest) as soon as practicable after the closing date of the Offer.

Pending the allotment and issue of the Shares or payment of refunds under this Offer Document, all Application Monies will be held by the Company in trust for the Investor in a separate bank account as required by the Corporations Act. The Company, however, will be entitled to retain all interest that accrues on the bank account and each Investor waives the right to claim interest.

Holding statements for Offer Shares and the Additional Shares will be mailed in accordance with the ASX Listing Rules and the timetable set out in section 1.2 of this Offer Document.

#### **4.16 Offer Document and the Corporations Act**

This Offer Document is issued pursuant to section 708AA of the Corporations Act without disclosure to investors under Part 6D.2 of the Corporations Act.

Accordingly, neither this Offer Document nor the Entitlement and Acceptance Form are required to be lodged or registered with ASIC and no prospectus for the offer will be prepared. In general terms, section 708AA permits certain companies to undertake rights issues without being required to use or provide to shareholders a prospectus or other disclosure document. Accordingly, the level of disclosure in this Offer Document is significantly less than the level of disclosure required in, and what you would ordinarily expect in, a prospectus.

In accordance with the conditions imposed on the Company by section 708AA of the Corporations Act, the Company provided ASX with a notice that complied with the requirements of section 708AA(7) on 20 January 2022. The notice was required to:

- (a) set out information that had been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules and that Investors and their professional advisers would reasonably require, and would reasonably expect to find in a disclosure document, for the purpose of making an informed assessment of:
  - (i) assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
  - (ii) the rights and liabilities attaching to the Shares offer under this Offer Document; and
- (b) state the potential effect of the issue of the Shares offer under this Offer Document on the control of the Company and the consequences of that effect.

#### **4.17 Overseas Shareholders**

This Offer Document has been prepared to comply with the requirements of the securities laws of Australia.

This Offer Document does not constitute an offer in any jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer. No action has been taken to register or qualify the Offer, the Offer Document or the Offer Shares, or otherwise permit the public offering of the Offer Shares, in any jurisdiction other than Australia.

The distribution of this Offer Document (including an electronic copy) outside Australia and New Zealand may be restricted by law. If you come into possession of this Offer Document, you should observe such restrictions and should seek your own advice on such restrictions.

Shareholders resident in Australia or New Zealand holding Shares on behalf of persons who are resident overseas are responsible for ensuring that taking up an Entitlement under the Offer does not breach regulations in the relevant overseas jurisdiction. Return of a duly completed Entitlement and Acceptance Form will be taken by the Company to constitute a representation that there has been no breach of those regulations.

Any non-compliance with these restrictions may contravene applicable securities laws.

### **New Zealand**

The Offer Shares are not being offered or sold to the public within New Zealand other than to existing Shareholders of the Company with registered addresses in New Zealand to whom the Offer of Offer Shares is being made in reliance on the transitional provisions of the *Financial Markets Conduct Act 2013* (New Zealand) and the *Financial Markets Conduct (Incidental Offers) Exemption Notice 2016* (New Zealand).

This document has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority under the *Financial Markets Conduct Act 2013* (New Zealand). This document is not an investment statement or prospectus under New Zealand law and is not required to, and may not, contain all the information that an investment statement or prospectus under New Zealand law is required to contain.

### **United States**

None of the information in this Offer Document, or the Entitlement and Acceptance Form that will accompany this Offer Document when it is despatched to Eligible Shareholders, constitutes an offer to sell, or the solicitation of an offer to buy, any securities in US. Neither this Offer Document (or any part of it), the accompanying ASX announcements nor the Entitlement and Acceptance Form when that is to be made available, may be released or distributed directly or indirectly, to persons in US.

The Offer Shares have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of US. The Entitlements may not be taken up by persons in US or by persons (including nominees or custodians) who are acting for the account or benefit of a person in US, and the Offer Shares may not be offered, sold or resold in US or to, or for the account or benefit of, a person in US except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act of 1933 and applicable securities laws of any state or other jurisdiction in US.

Ineligible Shareholders are not entitled to participate in the Entitlement Offer.

#### **4.18 Enquiries**

Any questions concerning the Offer should be directed to the Company's Share Registry, Computershare on 1300 855 080 (within Australia) or +61 3 9415 4000 (outside Australia) Monday to Friday 8:30am – 5:00pm AEDT.



## 5. Purpose and effect of the Offer

---

### 5.1 Use of funds raised

Completion of the Offer will result in an increase in cash at hand of up to approximately \$3.4 million (before the payment of the costs associated with the Offer).

The Company intends to apply the funds raised under the Offer and the proceeds of the Placement (approximately \$5.7 million in total) to:

- (a) finalise the depressive burden validation trial and submit the data for FDA approval pursuant to a De Novo application;
- (b) establish the depressive burden trial with Medibio's existing research partner, Medbridge Health, for monitoring of sleep disturbance patients in the home environment;
- (c) establish the trial with a commercial partner to monitor the effects of pharmaceuticals in psychiatric patients;
- (d) increase the promotion, sales and marketing activities for the Company's corporate and consumer products, ilumen and LUCA, particularly in the USA; and
- (e) general working capital.

The above statement is a statement of current intentions as at the date of this Offer Document. As with any budget, intervening events and new circumstances have the potential to affect the manner in which the funds are ultimately applied. The Board reserves the right to alter the way funds are applied.

### 5.2 Effect of the Offer

The principal effect of the Offer will be to:

- (a) increase the cash reserves and issued capital by up to approximately \$3,435,091 immediately after completion of the Offer prior to deducting the estimated expenses of the Offer; and
- (b) increase the total number of Shares on issue from 2,061,051,123 (inclusive of the Stage 1 Placement Shares) by up to 687,018,109 Shares, such that there will be approximately 2,938,118,482 Shares on issue following completion of the Offer and factoring in the issue of the Stage 2 Placement Shares.

Please see section 5.3 of this Offer Document for further details.

### 5.3 Effect on capital structure

The effect of the Offer on the capital structure of the Company, assuming all Offer Shares are issued, is set out below.

Shares	Number
Shares on issue as at the date of Offer Document (including the Tranche 1 Placement Shares)	2,061,051,123
Shares offered pursuant to the Offer	687,018,109
Tranche 2 Placement Shares to be issued under the Tranche 2 Placement	190,049,250
<b>Total Shares on issue after completion of the Offer</b>	<b>2,938,118,482</b>

<b>Options</b>	<b>Number</b>
<b>Options on issue as at date of the Offer Document</b>	
Quoted Options expiring 28 February 2024, exercisable at \$0.015 per Option (MEBOC)	205,111,009
Unlisted Options, expiring 6 October 2023, exercisable at \$0.012 per Option (MEBAN)	10,210,500
Unlisted Options, expiring various dates and exercisable at various prices (MEBAD)	52,137,113
Unlisted Options, expiring 8 December 2025, exercisable at \$0.011 per Option (MEBAO)	11,250,000
Unlisted Options, expiring 2 June 2022, exercisable at \$0.03 per Option (MEBAE)	27,500,000
<b>Options offered pursuant to the Offer and Placement</b>	
Tranche 1 Placement Options to be issued under the Tranche 1 Placement	130,000,000
Tranche 2 Placement Options to be issued under the Tranche 2 Placement	95,024,625
Options to be issued under the Offer	343,509,055
Underwriter Options to be issued to the Underwriter	56,853,315
<b>Total options on issue after completion of the Offer</b>	<b>931,595,617</b>

#### **5.4 Possible dilutive effect**

The dilutionary effect of the Offer on your shareholding will depend on whether you are an Eligible Shareholder and if so, whether you elect to subscribe for some or all of your Entitlement.

If Eligible Shareholders take up all of their entitlements under the Offer, Eligible Shareholders will hold the same percentage interest in the Company as they did immediately prior to completion of the Offer.

However, to the extent that any Shareholder fails to take up their full Entitlement to Offer Shares under the Offer, or is are Ineligible Shareholders unable to participate in the Offer, that Shareholder's percentage holding in the Company will be diluted.

Please refer to Section 5.5 of this Offer Document for detail of the effect of the Offer on voting power in the Company.

#### **5.5 Effect of Offer on Voting Power in the Company**

As the acquisition of Shares under the Offer and Shortfall Offer does not satisfy the requirements of exception 10 of section 611 of the Corporations Act, no person (including the Underwriter or any sub-underwriters) will be entitled to acquire Offer Shares pursuant to the Offer or Shortfall Offer if to do so would result in their, or another person's, Voting Power in the Company increasing from 20% or below to more than 20%, or from a starting point above 20% to below 90%, unless an exception to the restrictions contained in section 606 of the Corporations Act applies.

Accordingly, as there are currently no exceptions to the restrictions contained in section 606 of the Corporations Act and in light of the size of the Offer, the Offer is not expected to have any material effect or consequence on the control of the Company.

Details of the control implications are set out below.

Shareholders should note that if they do not participate in the Offer, then following completion of the Offer and the Placement, their Voting Power will be diluted by 29.85%. Examples of how the dilution may impact Shareholders are set out below.

The below table assumes that:

- the Placement Shares are placed in accordance with the firm commitments received by the Company;
- no Shares are issued before the Record Date, as a result of the exercise of Options; and
- those Entitlements not accepted by the shareholder are placed as Additional Shares or subscribed by the Underwriter.

Holder	Record Date		Entitlement	Post-Tranche 2 Placement		Post-Offer	
	Shares	%		Shares	Shares	%	Shares
Shareholder 1	100,000,000	4.85%	33,333,333	100,000,000	4.44%	100,000,000	3.40%
Shareholder 2	50,000,000	2.43%	16,666,667	50,000,000	2.22%	50,000,000	1.70%
Shareholder 3	20,000,000	0.97%	6,666,667	20,000,000	0.89%	20,000,000	0.68%
<b>Total</b>	<b>2,061,051,123</b>	<b>100%</b>	<b>687,018,109</b>	<b>2,251,100,373</b>	<b>100%</b>	<b>2,938,118,482</b>	<b>100%</b>

Shareholders should also note that if all Shareholders do not take up their Entitlement and accordingly, are ineligible to subscribe for any Additional Shares, the Underwriter will obtain a maximum Voting Power of 29.85% of the Company. The table below sets out examples of the possible voting power of the Underwriter based on the participation of Shareholders in the Offer.

This table assumes that:

- the Placement Shares are placed in accordance with the firm commitments received by the Company;
- no Shares are issued before the Record Date, as a result of the exercise of Options; and
- those Entitlements not accepted are placed solely with the Underwriter or its associates.

Underwriter's Voting Power Pre-Offer	Total Shareholder take up of Entitlements	Shares taken up by Underwriter under Shortfall	Underwriter's Voting Power Post-Offer
0%	100%	-	0%
0%	50%	100,000,000	3.40%

0%	25%	150,000,000	5.11%
0%	0%	200,000,000	6.81%

## 5.6 Details of substantial holders

Based on publicly available information as at the close of trading on 19 January 2022, those persons which (together with their associates) have a relevant interest in 5% or more of the Shares on issue are set out below:

Substantial Shareholder	At date of Offer Document		On completion of Offer	
	Shares	%	Shares	%
FIL Limited	121,928,459	7.7%	121,928,459	4.44%
<b>Total</b>	121,928,459	7.7%	121,928,459	4.44%

If a substantial holder of the Company does not participate in the Offer, and the Offer and any Shortfall is fully subscribed, their holding will be diluted.

## **6. Risk Factors**

---

### **6.1 Introduction**

An investment in the Company is not risk free and should be regarded as speculative.

There are specific risks which relate directly to the Company's activities. In addition, there are other general risks, many of which are largely beyond the control of the Company and the Directors. The risks identified in this section, or other risk factors, may have a material impact on the financial performance of the Company and the market price of the Shares and the underlying Shares.

The following is not intended to be an exhaustive list of the risk factors to which the Company is exposed and do not take into account the individual circumstances of Shareholders.

The Directors strongly recommend potential Investors to consider the risk factors described below, together with information contained elsewhere in this Offer Document and consult with their professional advisers before deciding whether to apply for Shares under this Offer Document.

The following is not intended to be an exhaustive list of the risk factors to which the Company is exposed.

### **6.2 Specific risks**

#### **(a) Competition regulation and loss of reputation**

The health industry is intensely competitive and subject to rapid and significant change. A number of companies, both in Australia and abroad, may be pursuing the development of products that target the same markets that the company is targeting. The Company's products may compete with existing products that are already available to customers. In addition, a number of companies, both in Australia and abroad, may be pursuing the development of products that target the same customers that the Company is targeting. The Company may face competition from parties who have substantially greater resources.

#### **(b) Regulatory approvals and investigations**

The research, development, manufacture, marketing and sale of products using the Company's technology are subject to varying degrees of regulation by a number of government authorities in Australia and overseas. Specifically, the Company anticipates submitting a De Novo application to the U.S. Food and Drug Administration (**FDA**) in 2022 for its depression medical software device MEB-001, the FDA will review that application and determine if it is appropriate to clear MEB-001 for marketing in the US.

Such approval from the FDA is reliant on regulator interpretation of data from trial and other development activities, and can take longer, require additional work (including further trials) or may not be provided at all. As a result, the Company's development programs on MEB-001 and any other product requiring FDA approval, may be delayed, incurring additional cost and may require additional funding to obtain such approvals. Any disruption, delay or failure of the Company to obtain any necessary approvals could impact adversely on the Company.

In addition to regulatory approvals for applications made by the Company, the Company may also become subject to regulatory investigations by any one or more regulatory bodies for current or historical actions by the Company. Depending on the outcome of regulatory investigations, the Company may be fined or sanctioned and its reputation and brand may be negatively impacted, which could adversely affect its business prospects, financial condition and results of operation.

(c) **Dependence upon key personnel**

The Company depends on the talent and experience of its personnel as its primary asset. There may be a negative impact on the Company if any of its key personnel leave. It may be difficult to replace them, or to do so in a timely manner or at comparable expense. Additionally, any key personnel of the Company who leave to work for a competitor may adversely impact the Company.

In summary, the Company's ability to attract and retain personnel will have a direct impact on its ability to achieve its commercialisation and commitments. Additionally, increases in recruitment, wages and contractor costs may adversely impact upon the financial performance of the Company.

(d) **Requirement to raise additional funds**

The Company may be required to raise additional equity or debt capital in the future. There is no assurance that it will be able to raise that capital when it is required or, even if available, the terms may be unsatisfactory. If the Company is unsuccessful in obtaining funds when they are required, the Company may need to delay or scale down its operations.

(e) **Research & Development Grant (Commonwealth)**

Currently, the Company is eligible for an annual R&D Tax Incentive refund. The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditures on research and development. There is no guarantee that this program will continue or that the eligibility criteria will not change. Refunds are subject to audit by the Australian Tax Office and AusIndustry and repayment is required in certain circumstances, should the relevant regulators deem the claim is not in accordance with the relevant legalisation.

(f) **Growth**

There is a risk that the Company may be unable to manage its future growth successfully. The ability to hire and retain skilled personnel as outlined above may be a significant obstacle to growth.

(g) **Intellectual Property**

The Company's ability to leverage its innovation and expertise depends upon its ability to protect its intellectual property and any improvements to it. The intellectual property may not be capable of being legally protected, may be the subject of unauthorised disclosure, and may be unlawfully infringed. The Company may incur substantial costs in asserting or defending its intellectual property rights.

(h) **Risk of delay and continuity of operations**

The Company may experience delays in achieving some or all of its milestones, including but not limited to product development, obtaining regulatory approvals, or generating licensing opportunities and sales and revenue generation. The Company is also dependent on, amongst other things, its technology, key personnel and IT systems. Any disruption or delay to any key inputs could impact adversely on the Company.

(i) **Liability claims**

The Company may be exposed to liability claims, including but not limited to those that could arise in connection with its provision of services, such as if they are provided in fault and/or cause harm to its customers. As a result, the Company may have to expend significant financial and managerial resources to defend against such claims. If any such claim against the Company is successful, the Company may be fined or sanctioned and its reputation and brand may be negatively impacted,

which could adversely affect its business prospects, financial condition and results of operation.

The Company may be exposed to claims from employees, including those who have left the company or may leave it in future for unfair dismissal.

(l) **Contractual risks**

As a party to contracts, the Company may face claims of breach or noncompliance by a contracting party. No assurance can be given that all contracts will be fully performed by all contracting parties and that the Company will be successful in securing compliance with the terms of each contract by the relevant third party.

(m) **Exchange rate risk**

The expenditure of the Company is and will be in Australian and US currencies, exposing the Company to fluctuations and volatility of the rates of exchange between the Australian dollar and the US dollar as determined in international markets.

(n) **Commercialisation**

Developing software and technology involves the expenditure of significant funds and often involves an extended period of time to achieve a return on investment. While the Company's business strategy is to continue to make investments in innovation in the development and commercialisation of its technologies, the company may not generate significant revenues from these investments for several years (if at all).

(o) **COVID-19**

The COVID-19 pandemic and associated restrictions on social distancing imposed by governments has had and continues to have an impact on the Company business and in particular on the Company's operations in Minneapolis, US. Furthermore, the progress of the clinical trials undertaken by the Company in US has been hindered by the closure of sleep clinics across the US as a result of COVID-19.

It should be further noted of the possible impacts of COVID-19 on the FDA's ability continue to process applications in the normal course of ordinary business due to the pandemic impacts. As such, the Company may be impacted by delays in processing any submissions lodged with FDA, ultimately impacting the Company's progression.

There are also other changes in the domestic and global macroeconomic environment associated with the events relating to COVID-19 that are beyond the control of the Company and may be exacerbated in an economic recession or downturn. These include but are not limited to:

- changes in inflation, interest rates and foreign currency exchange rates;
- changes in employment levels and labour costs;
- changes in aggregate investment and economic output; and
- other changes in economic conditions which may affect the revenue or costs of the Company.

While it is difficult for the Company to quantify the extent and duration of the impact of the COVID-19 pandemic on the global economy, any sustained period of economic downturn as a result of the pandemic may disrupt or delay the Company's intended programs and may impact the Company's ability to raise capital in the near to medium-term future.

With the emergence of the COVID-19 pandemic and its impact on the global macroeconomic environment, there is the risk of future pandemics which may or may not be connected with COVID-19 or any future variants of the virus.

### **6.3 General risks**

#### **(a) Economic risks and market conditions**

Factors, such as, but not limited to, world economic conditions, political instability, stock market trends, interest rates, exchange rates, inflation levels, commodity prices, industrial disruption, environmental impacts, international competition, taxation changes and legislative or regulatory changes may all have an adverse impact on our revenues, operating costs, profit margins and Share price. These factors are beyond the control of the Company and the Company cannot predict how they will impact its business.

#### **(b) Changes in legislation and government regulation**

Government legislation in Australia or any other relevant jurisdiction, including changes to the taxation system, may affect future earnings and relative attractiveness of investing in the Company. Changes in government policy or statutory changes may affect the Company and the attractiveness of an investment in it.

#### **(c) Unforeseen risk**

There may be other risks which the Directors are unaware of at the time of issuing this Offer Document which may impact on the Company, its operations and/or the valuation and performance of the Company's securities.

#### **(d) Combination of risk**

The Company may not be subject to a single risk. A combination of risks, including any of the risks outlined in this Section could affect the performance valuation, financial performance and prospects of the Company.

#### **(e) Unforeseen expenditure risk**

Expenditure may need to be incurred that has not been taken into account in the preparation of this Offer Document. Although the Company is not aware of any additional expenditure requirements other than those announced on the ASX and disclosed in this Offer Document, if such expenditure is subsequently incurred, this may adversely affect the expenditure proposals of the Company.

#### **(f) Market conditions**

Equities market conditions may affect the value of the Company's quoted securities regardless of the Company's operating performance. Equities market conditions are affected by many factors such as:

- (i) general economic outlook;
- (ii) introduction of tax reform or other new legislation;
- (iii) interest rates and inflation rates;
- (iv) changes in investor sentiment toward particular market sectors;
- (v) the demand for, and supply of, capital; and
- (vi) terrorism or other hostilities.



The market price of securities can fall as well as rise and may be subject to varied and unpredictable influences on the market for equities in general and biotechnology stocks in particular. Neither the Company nor the Directors warrant the future performance of the Company or any return on an investment in the Company.

(g) **Additional requirements for capital**

The Company's capital requirements depend on numerous factors. Depending on the Company's ability to generate income from its operations, the Company may require further financing in addition to amounts raised under the Offer. Any additional equity financing will dilute shareholdings, and debt financing, if available, may involve restrictions on financing and operating activities. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations and may be prevented from progressing the commercialisation of its products. There is however no guarantee that the Company will be able to secure any additional funding or be able to secure funding on terms favourable to the Company.

(h) **Speculative investment**

The above list of risk factors ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. The above factors, and others not specifically referred to above, may in the future materially affect the financial performance of the Company and the value of the securities offered under this Offer Document.

Therefore, the Shares to be issued pursuant to this Offer Document carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those securities.

Potential investors should consider that an investment in the Company is speculative and should consult their professional advisers before deciding whether to apply for securities pursuant to this Offer Document.

## 7. Additional information

---

### 7.1 Continuous disclosure obligations

The Company is listed on the ASX and its Shares are quoted on the ASX under the code: MEB.

The Company is a 'disclosing entity' (as defined in section 111AC of the Corporations Act) and is subject to regular reporting and disclosure obligations under the Corporations Act and the ASX Listing Rules, including the preparation of annual reports and half yearly reports. The Company is required to disclose to ASX any information of which it is or becomes aware concerning the Company and which a reasonable person would expect to have a material effect on the price or value of the Company's securities.

This Offer Document is issued pursuant to section 708AA of the Corporations Act without disclosure to investors under Part 6D.2 of the Corporations Act.

This Offer Document is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX and does not include all of the information that would be included in a prospectus or other disclosure document that is required to satisfy the Corporations Act. Investors should therefore have regard to the other publicly available information in relation to the Company before making a decision whether or not to invest.

Having taken such precautions and having made such enquiries as are reasonable, the Company believes that it has complied with the general and specific requirements of ASX as applicable from time to time throughout the three months before the issue of this Offer Document which required the Company to notify ASX of information about specified events or matters as they arise for the purpose of ASX making that information available to the stock market conducted by ASX.

### 7.2 Market price of Shares

The Company is a disclosing entity for the purposes of the Corporations Act and its Shares are enhanced disclosure securities quoted on ASX.

The highest, lowest and last market sale prices of the Shares on ASX during the three months immediately preceding the date this Offer Document and the respective dates of those sales were:

	Share Price	Date
Highest	\$0.009	18 October 2021
Lowest	\$0.005	19 January 2022
Last	\$0.005	19 January 2022

### 7.3 Interests of Directors

The interests of the Directors hold either directly or through their controlled entities in the securities of the Company as at the date of this Offer Document are as follows:

Director	Shares	Options	Entitlement (Offer Shares)
Claude Solitario	52,220,086	24,150,000	17,406,695
Peter Carlisle	6,115,125	8,159,556	2,038,375

<b>Director</b>	<b>Shares</b>	<b>Options</b>	<b>Entitlement (Offer Shares)</b>
Melanie Leydin	Nil	4,800,000	Nil

The Board recommends all Eligible Shareholders take up their Entitlements.

#### **7.4 Financial forecasts**

The Directors have considered the matters set out in ASIC Regulatory Guide 170 and believe that they do not have a reasonable basis to forecast future earnings on the basis that the operations of the Company are inherently uncertain. Accordingly, any forecast or projection information would contain such a broad range of potential outcomes and possibilities that it is not possible to prepare a reliable best estimate forecast or projection.

#### **7.5 Clearing House Electronic Sub-Register System (CHES) and Issuer Sponsorship**

The Company currently operates an electronic issuer-sponsored register and an electronic CHES sub-register. The two sub-registers together will comprise the Company's register of Shares.

The Company will not issue certificates. Investors who are allotted Shares under this Offer Document will be provided with a transaction confirmation statement which sets out the number of Shares allotted to the Investor. Investors who elect to hold Shares on the issuer-sponsored sub-register will be provided with a holding statement (similar to a bank account statement) which sets out the number of Shares allotted to the Shareholder under this Offer Document. For Investors who elect to hold their Shares on the CHES sub-register, the Company will issue an advice that sets out the number of the Shares allotted to the Investor under this Offer Document. At the end of the month of allotment, CHES, acting on behalf of the Company, will provide those Shareholders with a holding statement that confirms the number of Shares held and any transactions during that month.

A holding statement (whether issued by CHES or the Company) will also provide details of the applicable Holder Identification Number in case of a holding on the CHES sub-register or Reference Number in case of a holding on the issuer-sponsored sub-register. Following distribution of these initial holding statements, a holding statement will also be provided to each Shareholder at the end of any subsequent month during which the balance of that Shareholder's holding of securities in the Company changes.

A Shareholder may request a holding statement at any other time. However, a charge may be imposed by the Share Registry for additional statements.

#### **7.6 Privacy Act**

If you complete an application for Shares, you will be providing personal information to the Company (directly or by the Share Registry). The Company collects, holds and will use that information to assess your application, service your needs as a holder of equity securities in the Company, facilitate distribution payments and corporate communications to you as a Shareholder and carry out administration.

The information may also be used from time to time and disclosed to persons inspecting the register, bidders for your securities in the context of takeovers, regulatory bodies, including the Australian Taxation Office, authorised securities brokers, print service providers, mail houses and the Share Registry.

You can access, correct and update the personal information that we hold about you. Please contact the Company or the Share Registry if you wish to do so at the relevant contact numbers set out in this Offer Document.

Collection, maintenance and disclosure of certain personal information is governed by legislation including the *Privacy Act 1988* (Cth), the Corporations Act and certain rules such as the ASX Settlement Operating Rules. You should note that if you do not provide the

information required on the application for Shares, the Company may not be able to accept or process your application.

If you do not provide the information required on the Entitlement and Acceptance Form, the Company may not be able to accept or process the application.

#### **7.7 Rights issue exception not available**

No nominee has been appointed for Ineligible Shareholders under section 615 of the Corporations Act and, as such, Eligible Shareholders will not be able to rely on the exception for rights issues in Item 10 of Section 611 of the Corporations Act. Accordingly, when an Eligible Shareholder applies for some or all of their Entitlement, they must have regard to section 606 of the Corporations Act. Eligible Shareholders who may be at risk of exceeding the 20% Voting Power threshold in section 606 as a result of acceptance of their Entitlement or subscribing for Additional Shares pursuant to the Shortfall Offer should seek professional advice before completing and returning the Entitlement and Acceptance Form.

#### **7.8 Litigation**

So far as the Company is aware, there are no legal or arbitration proceedings, active or threatened against, or being brought by, the Company which may have a material effect on the Company's financial position.

#### **7.9 No cooling-off rights**

Cooling-off rights do not apply to an investment in Offer Shares. You cannot, in most circumstances, withdraw your application once it has been accepted.

#### **7.10 Alteration of terms**

The Company reserves the right, at its discretion, to vary all or part of the Offer at any time, subject to the Corporations Act and ASX Listing Rules and any other law or regulation to which the Company is subject.

#### **7.11 Placement**

The Company has entered into a capital raising mandate with the Underwriter on 11 December 2021 (**Underwriter Mandate**), pursuant to which the Underwriter has agreed to manage the Placement. The Company has agreed to pay to the Underwriter the follow fees:

- (a) an aggregate fee of 6% (plus GST) of the total gross amount raised under the Placement; and
- (b) an entitlement to subscribe for options to acquire shares in the Company at an issue price of \$0.00001 per option on the basis of ten (10) options for every \$1.00 of all funds raised under the Offer and Placement. Such options will be in the same class and on the same terms as the Attaching Options (i.e. MEBOC) (**Underwriter Options**);
- (c) In addition, the Company has agreed to pay the Underwriter a monthly retainer fee of \$6,000 (excluding GST) for ongoing corporate advisory services for a period of 24 months.

#### **7.12 Underwriting**

The Company has entered into an underwriting agreement with the Underwriter dated 20 January 2022 (**Underwriting Agreement**), pursuant to which the Underwriter has agreed to partially underwrite the Offer for an amount up to \$1 million by procuring Applications for any Offer Shares that are not subscribed for by Eligible Shareholders pursuant to the Offer. The Underwriter has the right to, in consultation with the Company, nominate and determine who is to receive all of the Offer Shares not subscribed for as Entitlement.

The Underwriter will only be required to perform its underwriting obligations if the Company receives valid applications for less than \$1 million.

The Company has agreed to pay to the Underwriters the following fees:

- (a) an issue management fee of \$20,000;
- (b) an aggregate fee of 6% (plus GST) of the total amount underwritten by the Underwriter; and
- (c) an entitlement to subscribe for the Underwriter Options.

The Company will also be required to indemnify the Underwriters for certain costs and expenses incurred by it in relation to the Offer, including certain legal fees.

The Underwriting Agreement contains various representations, warranties, indemnities and undertakings in favour of the Underwriters that are not unusual for an underwriting arrangement of this sort. In particular, the Underwriting Agreement contains various representations and warranties by the Company relating to the Company and its business, including information provided to the Underwriter and disclosed to the ASX. The Underwriting Agreement also imposes various obligations on the Company, including undertakings to do certain things, including providing certain notices to the Underwriter and the ASX within prescribed periods. The Underwriting Agreement also places certain restrictions on the Company for a period of three months from the date of the Underwriting Agreement, including restrictions on amendments to its constitution, disposing of the whole or a substantial part of its business or property and restrictions on the issue of Shares by the Company.

The obligation of the Underwriter to underwrite the Offer is conditional on customary conditions including, amongst others, the dispatch of this Offer Document and certain events not occurring during the period the Offer is open.

If certain events occur, the Underwriter has the right to terminate the Underwriting Agreement. In summary, these include (terms below as defined in the Underwriting Agreement, unless the context indicates otherwise):

- (a) (Indices fall): any of the All Ordinaries Index, XKO 3510 Health Eq & Services Index or the Standard and Poors/ASX Small Resources Index as published by ASX is at any time after the date of the Underwriting Agreement at a level that is 10% or more below its respective level as at the close of business on the Business Day prior to the date of the Underwriting Agreement; or
- (b) (No Official Quotation): ASX has indicated before the Shortfall Notice Deadline Date that Official Quotation will not be granted in accordance with the Timetable or will be granted with such conditions attached so as to represent a Material Adverse Effect (as defined below), having been granted, is subsequently withdrawn, withheld or qualified; or
- (c) (Restriction on allotment): the Company is prevented from allotting the Offer Shares and Attaching Options (**Offer Securities**) within the time required by the Underwriting Agreement, the Corporations Act, the ASX Listing Rules, any statute, regulation or order of a court of competent jurisdiction by ASIC, ASX or any court of competent jurisdiction or any governmental or semi-governmental agency or authority; or
- (d) (Misleading statement): it transpires that there is a statement or omission made by the Company including without limitation a statement or omission in the Offer Document or otherwise in connection with the Offer, the Placement or an ASX announcement relating to the Offer or the Placement and that statement or omission is or becomes misleading or deceptive or likely to mislead or deceive; or
- (e) (ASIC or other prosecution): ASIC gives notice of an intention to hold a hearing, examination or investigation, or it requires information to be disclosed in connection with the Offer, the Placement or the Company; or

- (f) (Takeovers Panel): the Takeovers Panel makes a declaration that circumstances in relation to the affairs of the Company are unacceptable circumstances under Pt 6.10 of the Corporations Act, or an application for such a declaration is made to the Takeovers Panel and the Takeovers Panel elects to hear the application; or
- (g) (Hostilities): there is an outbreak of hostilities or a material escalation of hostilities (whether or not war has been declared) after the date of the Underwriting Agreement involving one or more of Australia, New Zealand, Japan, Russia, the United Kingdom, the United States of America, or the Peoples Republic of China or any member of the European Union, or a terrorist act is perpetrated on any of those countries or any diplomatic, military, commercial or political establishment of any of those countries anywhere in the world; or
- (h) (Authorisation): any authorisation which is material to anything referred to in the Offer is repealed, revoked or terminated or expires, or is modified or amended in a manner unacceptable to the Underwriter; or
- (i) (Indictable offence): a director or a senior manager of the Company and each of its subsidiaries (**Relevant Company**) is charged with an indictable offence; or
- (j) (Termination Events): in the reasonable opinion of the Underwriter reached in good faith, the occurrence of a Termination Event has or is likely to have, or two or more Termination Events together have or are likely to:
  - (i) have a Material Adverse Effect, being:
    - (A) a material adverse effect which is likely to result in the price of Shares on ASX falling by more than 10% during a period of one week; or
    - (B) a material adverse effect on the assets, condition, trading or financial position, performance, profits and losses, results, prospects, business or operations of the Company and its subsidiaries either individually or taken as a whole; or
    - (C) a material adverse effect on the tax position of either:
      - (1) the Company and its subsidiaries either individually or taken as a whole; or
      - (2) a majority of Australian resident shareholders in the Company; or
  - (ii) could give rise to a liability of the Underwriter under the Corporations Act or otherwise, and,

any of the following events occurs:

- (i) (Default): default or breach by the Company under the Underwriting Agreement of any material terms, condition, covenant or undertaking;
- (ii) (Contravention of constitution or Act): a contravention by a Relevant Company of any provision of its constitution, the Corporations Act, the ASX Listing Rules or any other applicable legislation or any policy or requirement of ASIC or ASX;
- (iii) (Adverse change): an event occurs that causes a Material Adverse Effect in the assets, liabilities, financial position, trading results, profits, forecasts, losses, prospects, business or operations of any Relevant Company including, without limitation, if any forecast disclosed to ASX prior to the date of the Underwriting Agreement becomes incapable of being met or in the Underwriter's reasonable opinion, unlikely to be met in the projected time;

- (iv) (Public statements): without the prior approval of the Underwriter a public statement is made by the Company in relation to the Offer or the Placement;
- (v) (Change in Act or policy): there is introduced, or there is a public announcement of a proposal to introduce, into the Parliament of Australia or any of its States or Territories any Act or prospective Act or budget or the Reserve Bank of Australia or any Commonwealth or State authority adopts or announces a proposal to adopt any new, or any major change in, existing, monetary, taxation, exchange or fiscal policy;
- (vi) (Prescribed Occurrence): a Prescribed Occurrence occurs, being:
  - (A) a Relevant Company converting all or any of its Shares into a larger or smaller number of Shares;
  - (B) a Relevant Company resolving to reduce its share capital in any way;
  - (C) a Relevant Company:
    - (1) entering into a buy back agreement or;
    - (2) resolving to approve the terms of a buy back agreement under section 257C or 257D of the Corporations Act;
  - (D) a Relevant Company making an issue of, or granting an option to subscribe for, any of its Shares, or agreeing to make such an issue or grant such an option, other than an issue or agreement to issue in accordance with the Offer, the terms of the Underwriting Agreement or in a manner contemplated by the Underwriter Mandate (including the Underwriter Options Options) or otherwise with the prior written consent of the Underwriter;
  - (E) a Relevant Company issuing, or agreeing to issue, convertible notes;
  - (F) a Relevant Company disposing, or agreeing to dispose, of the whole, or a substantial part, of its business or property;
  - (G) a Relevant Company charging, agreeing to charge, the whole, or a substantial part, of its business or property;
  - (H) a Relevant Company resolving that it be wound up;
  - (I) the appointment of a liquidator or provisional liquidator to a Relevant Company;
  - (J) the making of an order by a court for the winding up of a Relevant Company;
  - (K) an administrator of a Relevant Company, being appointed under section 436A, 436B or 436C of the Corporations Act;
  - (L) a Relevant Company executing a deed of company arrangement; or
  - (M) the appointment of a receiver, or a receiver and manager, in relation to the whole, or a substantial part, of the property of a Relevant Company.;
- (vii) (Suspension of debt payments): the Company suspends payment of its debts generally;

- (viii) (Event of Insolvency): an Event of Insolvency occurs in respect of a Relevant Company, being:
  - (A) a receiver, manager, receiver and manager, trustee, administrator, Controller or similar officer is appointed in respect of a person or any asset of a person;
  - (B) a liquidator or provisional liquidator is appointed in respect of a corporation;
  - (C) any application (not being an application withdrawn or dismissed within 7 days) is made to a court for an order, or an order is made, or a meeting is convened, or a resolution is passed, for the purpose of:
    - (D) appointing a person referred to in paragraphs (a) or (b);
    - (E) winding up a corporation; or
    - (F) proposing or implementing a scheme of arrangement;
  - (G) any event or conduct occurs which would enable a court to grant a petition, or an order is made, for the bankruptcy of an individual or his estate under any Insolvency Provision;
  - (H) a moratorium of any debts of a person, or an official assignment, or a composition, or an arrangement (formal or informal) with a person's creditors, or any similar proceeding or arrangement by which the assets of a person are subjected conditionally or unconditionally to the control of that person's creditors or a trustee, is ordered, declared, or agreed to, or is applied for and the application is not withdrawn or dismissed within 7 days;
  - (I) a person becomes, or admits in writing that it is, is declared to be, or is deemed under any applicable Act to be, insolvent or unable to pay its debts; or
  - (J) any writ of execution, garnishee order, mareva injunction or similar order, attachment, distress or other process is made, levied or issued against or in relation to any asset of a person.;
- (ix) (Judgment against a Relevant Company): a judgment in an amount exceeding \$50,000 is obtained against a Relevant Company and is not set aside or satisfied within 7 days;
- (x) (Litigation): litigation, arbitration, administrative or industrial proceedings are after the date of the Underwriting Agreement commenced or threatened against any Relevant Company, other than any claims disclosed to the ASX prior to the date of the Underwriting Agreement;
- (xi) (Board and senior management composition): there is a change in the composition of the board or a change in the senior management of the Company before completion (in accordance with the Underwriting Agreement) without the prior written consent of the Underwriter (such consent not to be unreasonably withheld);
- (xii) (Change in shareholdings): there is a material change in the major or controlling shareholdings of a Relevant Company or a takeover offer or scheme of arrangement pursuant to Chapter 5 or 6 of the Corporations Act is publicly announced in relation to a Relevant Company;
- (xiii) (Timetable): there is a delay in any specified date in the Timetable which is greater than 3 Business Days;



- (xiv) (Force Majeure): a Force Majeure affecting the Company's business or any obligation under the Agreement lasting in excess of 7 days occurs;
- (xv) (Certain resolutions passed): a Relevant Company passes or takes any steps to pass a resolution under section 254N, section 257A or section 260B of the Corporations Act or a resolution to amend its constitution, except as disclosed to ASX or to the Underwriter prior to the date of the Underwriting Agreement or with the prior written consent of the Underwriter (which must not be unreasonably withheld or delayed);
- (xvi) (Capital Structure): any Relevant Company alters its capital structure in any manner not contemplated by the Offer, the Underwriting Agreement or the Underwriter Mandate;
- (xvii) (Investigation): any person is appointed under any legislation in respect of companies to investigate the affairs of a Related Company;
- (xviii) (Market Conditions): a suspension or material limitation in trading generally on ASX occurs or any material adverse change or disruption occurs in the existing financial markets, political or economic conditions of Australia, Japan, the United Kingdom, the United States of America or other international financial markets;
- (xix) (Shares are not fully paid ordinary): all Shares issued pursuant to the Offer and in accordance with the terms of the Underwriting Agreement must, from the date of allotment, rank equally in all respects with other fully paid ordinary shares in the Company and will be free of all encumbrances; or
- (xx) (Suspension): the Company is removed from the Official List or, after the date of the Underwriting Agreement, the Shares become suspended from Official Quotation and that suspension is not lifted within 3 trading days following such suspension.

## 8. Definitions

---

**\$** or **Dollars** means dollars in Australian currency (unless otherwise stated).

**AEDT** means Australian Eastern Daylight Savings Time.

**Additional Shares** has the meaning given to that term in section 4.13 of this Offer Document.

**Applicant** means an Eligible Shareholder has submitted an Application.

**Application** means an application for Offer Shares or Additional Shares pursuant to this Offer Booklet.

**Application Monies** means monies received by the Company from Applicants with respect to the Entitlement and Acceptance Form.

**ASIC** means the Australian Securities and Investments Commission.

**ASTC** means ASX Settlement Pty Ltd ACN 008 504 532.

**ASX** means ASX Limited ACN 008 624 691 or the financial market operated by it, as the context requires.

**ASX Listing Rules** means the listing rules of the ASX.

**ASX Settlement Operating Rules** means the settlement rules of the securities clearing house which operates CHESS.

**Attaching Option** means a free attaching quoted MEBOC Option, offered to participants in the Offer (or where the context requires, under the Shortfall Offer) for nil consideration on the basis of an entitlement to one (1) Attaching Option for every two (2) Offer Shares issued, and such Attaching Option issued on the terms and conditions set out in the Schedule to this Offer Document.

**Board** means the board of Directors unless the context indicates otherwise.

**Business Day** means a day that is not a Saturday, Sunday or a public holiday in Melbourne, Victoria.

**CHESS** means Clearing House Electronic Sub-register System of ASTC.

**Closing Date** means 5.00pm (AEDT) on the date specified in the timetable set out at section 1.2 this Offer Document or such other date as may be determined by the Directors.

**Company** means Medibio Limited ACN 008 130 336.

**Constitution** means the constitution of the Company as at the date of this Offer Document.

**Corporations Act** means the *Corporations Act 2001* (Cth), as amended.

**Directors** means the directors of the Company as at the date of this Offer Document.

**EGM** means the Extraordinary General Meeting to be held on 11 February 2022 to approve, among other things, the issue of the Tranche 2 Placement Shares, the Placement Options and the Underwriter Options.

**Eligible Shareholder** has the meaning given to that term in section 4.6 of this Offer Document.

**Entitlement** means the non-renounceable entitlement for Eligible Shareholders to subscribe for Offer Shares on the basis of one (1) Offer Share for every three (3) Shares held on the Record Date.

**Entitlement and Acceptance Form** means the entitlement and acceptance form either attached to or accompanying this Offer Document.

**Ineligible Shareholders** means any Shareholder who is not an Eligible Shareholder.

**Issue Price** means \$0.005 (0.5 cents) per Offer Share.

**Investor** means an investor participating in the Offer.

**Listing Rules** means the official listing rules of ASX, as amended from time to time.

**Offer** means the non-renounceable entitlement issue of one (1) New Share for every three (3) Shares held by those Eligible Shareholders registered at the Record Date at the Issue Price.

**Offer Document** means this document dated, 20 January 2022 under which the Offer is made, and includes any amended or replacement summary document.

**Offer Share** means a new fully paid Share in the capital of the Company to be issued pursuant to the Offer or Shortfall Offer.

**Official Quotation** means official quotation on ASX.

**Option** means an option to acquire a Share.

**Optionholder** means a holder of an Option.

**Placement** means the Tranche 1 Placement and Tranche 2 Placement.

**Placement Shares** means the Tranche 1 Placement Shares and the Tranche 2 Placement Shares issued pursuant to the Tranche 1 Placement and Tranche 2 Placement respectively.

**Placement Options** means Tranche 1 Placement Options and the Tranche 2 Placement Options.

**Record Date** means 7.00pm (AEDT) on the date specified in the timetable set out at section 1.2 this Offer Document.

**Regulation S** means Regulation S promulgated under the US Securities Act.

**Share** means a fully paid ordinary share in the capital of the Company.

**Share Registry** means Computershare Investor Services Pty Limited ACN 078 279 277.

**Shareholder** means a holder of a Share.

**Shortfall** means the extent to which Eligible Shareholders do not subscribe for New Shares (including Additional Shares) pursuant to the Entitlement Offer.

**Shortfall Offer** means the entitlement offer to Eligible Shareholders to subscribe for Additional Shares in excess of their Entitlement in accordance with section 4.13 of this Offer Document.

**Tranche 1 Placement** means the placement undertaken by the Company on 15 December 2021 under which the Tranche 1 Placement Shares were issued to sophisticated investors and professional investors to raise \$1.3 million (before costs and expenses) in accordance with sections 708(8) and 708(11) of the Corporations Act.

**Tranche 2 Placement** means the placement undertaken by the Company on 15 December 2021 under which the Tranche 2 Placement Shares are to be issued to sophisticated investors and professional investors, subject to shareholder approval at the EGM, and to raise \$950,246.25 (before costs and expenses) in accordance with sections 708(8) and 708(11) of the Corporations Act.

**Tranche 1 Placement Options** means approximately 130,000,000 free attaching Options issued in the same class and on the same terms as the Attaching Options in connection with the Tranche 1 Placement.

**Tranche 2 Placement Options** means approximately 95,024,625 free attaching Options issued in the same class and on the same terms as the Attaching Options in connection with the Tranche 2 Placement.

**Tranche 1 Placement Shares** means approximately 260,000,000 Shares issued without shareholder approval under the Company's existing placement capacity pursuant to ASX Listing Rule 7.1 and pursuant to the Tranche 1 Placement.

**Tranche 2 Placement Shares** means approximately 190,049,250 Shares issued subject to shareholder approval at the EGM pursuant to the Tranche 2 Placement.

**Underwriter** means CPS Capital Group Pty Ltd ACN 088 055 636.

**Underwriter Options** has the meaning given to that term in section 7.11(b).

**Underwriting Agreement** means the underwriting agreement between the Underwriter and the Company dated 20 January 2022, as summarised in section 7.11 of this Offer Document.

**US** means the United States of America.

**US Person** means, among other things and subject to certain exceptions:

- (a) any natural person resident in the US;
- (b) any partnership, corporation or other entity organised or incorporated in the US;
- (c) any trust of which any trustee is a US person;
- (d) any agency or branch of a foreign entity located in the US;
- (e) any account held by a dealer or other fiduciary that either is organised, incorporated or resident in the US or holds for the benefit or account of a US Person; or
- (f) any partnership or corporation that is organised or incorporated in a foreign jurisdiction by a US person principally for the purpose of investing in securities not registered under the US Securities Act.

**US Securities Act** means the *United States Securities Act of 1933*, as amended.

**Voting Power** has the meaning given to that term in the Corporations Act.

## 9. Corporate Directory

---

### Directors

Mr Claude Solitario  
Managing Director & CEO

Mr Peter Carlisle  
Non-Executive Director

Ms Melanie Leydin  
Non-Executive Director

### Company Secretary

Mr Mathew Watkins

### Share Registry

Computershare Investor Services Pty Limited  
GPO Box 2975  
Melbourne VIC 3001

Telephone: 1300 855 080 (within  
Australia) or +61 3 9415 4000 (outside  
Australia)

Offer Website:  
<https://meb2022entoffer.thereachagency.com>

Website: [www.investorcentre.com.au](http://www.investorcentre.com.au)

### Registered Office

Level 4, 96-100 Albert Road  
South Melbourne, Victoria 3205

Telephone: +61 3 9692 7222  
Facsimile: +61 3 9077 9233  
Website: [www.medibio.com.au](http://www.medibio.com.au)

### Legal adviser

Gadens  
Level 13, Collins Arch  
447 Collins Street  
MELBOURNE VIC 3000

### ASX Code

MEB

## Schedule – Rights and liabilities attaching to the Attaching Options

---

### Terms of Options

The Attaching Options to be issued under the Offer and the Placement entitle the holder to subscribe for Shares on the following terms and conditions.

#### (a) Entitlement

- (i) Each Attaching Option entitles the Attaching Option holder to subscribe for, and be allotted, one ordinary Share in the capital of the Company.
- (ii) Shares issued on the exercise of Attaching Options will rank equally with all existing Shares on issue, as at the exercise date, and will be subject to the provisions of the Constitution of the Company and any escrow restrictions imposed on them by the ASX.

#### (b) Exercise of Attaching Option

- (i) The Attaching Options are exercisable at any time from the issue date.
- (ii) The Attaching Options expire on 28 February 2024.
- (iii) The exercise price per Attaching Option is \$0.015 (1.5 cents).
- (iv) Each Attaching Option is exercisable by the Attaching Option holder signing and delivering a notice of exercise of Attaching Option together with the exercise price in full for each Share to be issued upon exercise of each Attaching Option to the Company's Share Registry. Unless a holder is exercising all of their Attaching Options, Attaching Options must be exercised in parcels of not less than 1,000.
- (v) The Attaching Options cannot be exercised if, as a result of the exercise, the Attaching Optionholder or any of its associates would breach the provisions of Chapter 6 (and specifically section 606) of the Corporations Act.
- (vi) Remittances must be made payable to 'Medibio Limited'.
- (vii) All Attaching Options will lapse on the earlier of the:
  - (A) receipt by the Company of notice from the Attaching Option holder that the Attaching Option holder has elected to surrender the Attaching Option; and
  - (B) expiry of the final date and time for exercise of the Attaching Option.
- (viii) In the event of liquidation of the Company, all unexercised Attaching Options will lapse.

#### (c) Quotation

- (i) The Attaching Option are in an existing class of quoted options. Subject to meeting the requirements of the ASX Listing Rules and the Corporations Act, the Company intends to apply to the ASX for Official Quotation of the Attaching Options but makes no guarantee that it will make any such application, or that if an application for Official Quotation is made that it will be successful.
- (ii) If the Shares of the Company are quoted on the ASX, the Company will apply to the ASX for, and will use its best endeavours to obtain, quotation of all Shares issued on the exercise of any Attaching Options within 10 Business Days (as defined in the ASX Listing Rules) of issue. The Company gives no assurance that such quotation will be granted.

(d) **Participation in Securities Issues**

Subject to paragraph (e) below, the holder is not entitled to participate in new issues of securities without exercising the Attaching Options.

(e) **Participation in a Reorganisation of Capital**

- (i) In the event of any reconstruction or reorganisation (including consolidation, subdivision, reduction or return of the capital of the Company), the rights of an Attaching Option holder will be changed in accordance with the ASX Listing Rules applying to a restructure or reorganisation of the capital at the time of that restructure or reorganisation, provided always that the changes to the terms of the Attaching Options do not result in any benefit being conferred on the Attaching Option holder which is not conferred on Shareholders of the Company.
- (ii) In any reorganisation as referred to in paragraph (e)(i), Attaching Options will be treated in the following manner:
  - (A) in the event of a consolidation of the share capital of the Company, the number of Attaching Options will be consolidated in the same ratio as the ordinary share capital of the Company and the exercise price will be amended in inverse proportion to that ratio;
  - (B) in the event of a subdivision of the share capital of the Company, the number of Attaching Options will be subdivided in the same ratio as the ordinary share capital of the Company and the exercise price will be amended in inverse proportion to that ratio;
  - (C) in the event of a return of the share capital of the Company, the number of Attaching Options will remain the same and the exercise price will be reduced by the same amount as the amount returned in relation to each ordinary share;
  - (D) in the event of a reduction of the share capital of the Company by a cancellation of paid up capital that is lost or not represented by available assets where no securities are cancelled the number of Attaching Options and the exercise price of each Attaching Option will remain unaltered;
  - (E) in the event of a pro-rata cancellation of shares in the Company, the number of Attaching Options will be reduced in the same ratio as the ordinary share capital of the Company and the exercise price of each Attaching Option will be amended in inverse proportion to that ratio; and
  - (F) in the event of any other reorganisation of the issued capital of the Company, the number of Attaching Options or the exercise price or both will be reorganised (as appropriate) in a manner which will not result in any benefits being conferred on the Attaching Option holder which are not conferred on shareholders.